External Control Arms (ECA) in Phase 3 Trials: What Is Needed Now and in the Future to Enable Acceptance With Regulatory and HTA Bodies?

Author(s)

Helene Karcher, PhD, Novartis Pharma AG, Basel, Switzerland

This Discussion Group will focus on and feature speakers from the session External Control Arms (ECA) in Phase 3 Trials: What Is Needed Now and in the Future to Enable Acceptance With Regulatory and HTA Bodies? (Monday, May 8, 4:45pm – 5:45pm).

Seating is limited.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Code

155

Topic

Study Approaches

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×